Agfa launches the Security Services Roadmap

Article

Agfa announced the launch of the Security Services Roadmap – a portfolio of solutions to assist IT Managers in addressing security issues.

HIMSS Dallas, TX, February 14, 2005

Agfa announced the launch of the Security Services Roadmap - a portfolio of solutions to assist IT Managers in addressing security issues.

A cornerstone of Agfa's security portfolio is a comprehensive HIPAA compliance assessment and documentation package for healthcare providers. After completing a series of questionnaires, customers have documentation of their risk assessment, prioritized gaps, action items and employee training. The savings in time and consultant fees have delighted those customers who have used Agfa services to achieve HIPAA security compliance for the April 2005 deadline.

"Agfa set the standard for secure data transmission by being the first PACS vendor to pass the U.S. Air Force's requirements in the most comprehensive security test and evaluation procedures in the healthcare IT industry," says Dan Birach, Vice President of Services, Agfa HealthCare. "We've taken that expertise and raised the bar to provide customizable solutions that analyze and document HIPAA security compliance, secure remote service support, safeguard patient confidentiality and simplify the administration of user security profiles."

Agfa will continue to add solutions and services to meet the needs of customers. In the second quarter of 2005, the Windows-based departmental IMPAXTM is expected to successfully complete the rigorous government security evaluation and Agfa plans to add the Systems Management and Reporting Service to the Security Systems Roadmap portfolio. The Systems Management and Reporting Service will help customers enforce software configuration and virus protection policies, with minimal administrative effort. By the end of the summer, Agfa also plans to introduce the Audit Manager, an automated reporting application that tracks various auditing events such as unauthorized access.

End of message

About Agfa

The Agfa-Gevaert Group is one of the world's leading imaging companies. Agfa develops, manufactures and markets analogue and digital systems, intended mainly for the graphics industry and the healthcare markets.

Agfa's headquarters are in Mortsel, Belgium. The company is active in 40 countries and has agents in another 100 countries throughout the world. Together they achieved a turnover of 4,215 million euros in 2003.

Product and company information can be found on Agfa's home page on the World Wide Web at: www.agfa.com.

Agfa, the Agfa rhombus, IMPAX and See More. Do More. are trademarks of Agfa-Gevaert N.V., Belgium or its affiliates. All rights reserved.

Contacts:

Geertrui De Smet

Global PR Manager HealthCare

tel.: +32 (0) 3 444 73 06

fax: +32 (0) 3 444 72 85

e-mail: geertruidesmet@agfapress.com

Jeff Lewis

Media Relations Manager HealthCare, North America

tel.: 201-440-2500 x4192

e-mail: jeff.lewis@agfa.com

Johan Jacobs

Corporate Press Relations Manager

tel.: +32 (0)3 444 80 15

fax: +32 (0)3 444 74 85

e-mail: johan.jacobs@agfa.com

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.